Slingeland Ziekenhuis
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Slingeland Ziekenhuis in Doetinchem, clinical research in cardiovascular diseases focuses on major conditions such as atherosclerotic cardiovascular disease, atrial fibrillation, myocardial infarction, peripheral arterial disease, and heart failure. These studies are largely aimed at testing new treatments and prevention strategies that may lower the risk of serious heart and circulation events.
- Improving prevention of heart attack, stroke, and urgent revascularization in high-risk patients
- Evaluating therapies for atrial fibrillation and cardioembolic risk
- Studying approaches to better manage residual vascular risk in peripheral artery disease
Research here also includes personalized and outcome-focused care, with the goal of refining treatment choices for people living with chronic cardiovascular conditions.
Hemic and Lymphatic Diseases
In the field of hemic and lymphatic diseases, the site is involved in studies of acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma, follicular lymphoma, and marginal zone lymphoma. The research is centered on improving treatment effectiveness and finding better ways to balance disease control with tolerability.
- Testing new combinations for leukemia and high-risk myelodysplasia
- Comparing treatment options for relapsed or refractory lymphomas
- Exploring flexible treatment strategies in multiple myeloma
These trials reflect a strong interest in advancing care for blood cancers through more tailored and practical treatment approaches.
Neoplasms
Clinical trial activity in neoplasms covers several cancer types, including breast cancer, triple negative breast cancer, metastatic colorectal cancer, colon cancer, and non-metastatic resectable pancreatic cancer. The studies are designed to assess new therapies, optimize existing cancer treatment, and improve survival outcomes.
- Evaluating adjuvant and perioperative treatment strategies in pancreatic and colon cancer
- Studying targeted and immune-based approaches in breast cancer
- Assessing treatment adjustment strategies for advanced colorectal cancer
At Slingeland Ziekenhuis, oncology research supports more personalized cancer care, especially for patients with early-stage, residual, or advanced disease.
Nervous System Diseases
Research in nervous system diseases is mainly focused on multiple sclerosis, with studies looking at ways to individualize long-term treatment and maintain control of disease activity. The trials aim to improve how therapy is delivered while preserving effectiveness and safety.
- Personalizing treatment schedules for multiple sclerosis
- Reducing treatment burden while maintaining disease suppression
- Supporting more flexible, real-world care strategies
This work reflects a broader effort to make neurological treatment more adaptive to patient needs.
Nutritional and Metabolic Diseases
The nutritional and metabolic diseases portfolio includes studies in obesity, type 2 diabetes mellitus, and related cardiovascular risk conditions. These trials are examining whether newer therapies can improve metabolic control and reduce long-term complications.
- Testing treatments for obesity and overweight linked to cardiovascular risk
- Evaluating diabetes therapies with potential heart-protective benefits
- Studying approaches that target both metabolic disease and vascular outcomes
The research combines metabolic care with prevention of heart and vascular disease, highlighting a strong prevention-oriented focus.
Respiratory Tract Diseases
Within respiratory tract diseases, the site is involved in research on respiratory tract infection and hospitalized patients with acute respiratory illness. These trials are aimed at improving recovery, reducing mortality, and identifying better treatment options for serious infections.
- Assessing interventions for hospitalized respiratory infections
- Improving outcomes in acute community-acquired pneumonia
- Supporting better care for patients with severe respiratory illness
The studies address a clinically important area where faster recovery and better survival can make a major difference.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 70 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 65 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Slingeland Ziekenhuis
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 70 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
